Latest research on BG-12

Dimethyl fumarate is an anti-inflammatory. It is indicated for multiple sclerosis patients with relapsing forms and is also being investigated for the treatment of psoriasis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera.

BG-12 interactions

A number of oral drugs has also recently been approved including fingolimod (Gilenya), dimethyl fumarate (Tecfidera) and teriflunomide (Aubagio), while oral Cladribine (Movectro) has been withdrawn following difficulties in licensing and laquinimod is still under investigation. [source, 2015]
Three new oral DMTs have been approved for the treatment of MS: fingolimod (Gilenya, Novartis, FDA Orange Book approval date September 21, 2010), teriflunomide (Aubagio, Genzyme/Sanofi, FDA Orange Book approval date September 12, 2012), and dimethyl fumarate (Tecfidera, Biogen Idec, FDA Orange book approval date March 27, 2013). [source, 2015]
Currently available DMTs include glatiramer acetate (GA; Copaxone, Teva Pharmaceuticals USA, Inc., North Wales, PA), intramuscular interferon beta-1a (IFNβ-1a IM; Avonex, Biogen Idec, Cambridge, MA), subcutaneous interferon beta-1a (IFNβ-1a SC; Rebif, EMD Serono Inc., Rockland, MA), interferon beta-1b (IFNβ-1b; Betaseron, Bayer Healthcare Pharmaceuticals, Inc., Montville, NJ; Extavia; Novartis Pharmaceutical Corporation, East Hanover, NJ), natalizumab (NZ; Tysabri, Biogen Idec, Cambridge, MA), fingolimod (FG; Gilenya, Novartis Pharmaceutical Corporation, East Hanover, NJ), teriflunomide (TF; Aubagio, Genzyme Corporation, Cambridge, MA) and dimethyl fumarate (DF; Tecfidera, Biogen Idec, Cambridge, MA). [source, 2014]
Approved treatments include interferons (Avonex, Betaferon, Betaseron, Extavia, Rebif), glatiramer acetate (Copaxone), natalizumab (Tysabri), and, more recently, the oral treatments teriflunomide (Aubagio), fingolimod (Gilenya), and dimethyl fumarate (Tecfidera). [source, 2014]
The Twitter resource, Topsy ( http://topsy.com/), which houses all tweets made since 2006, was searched for the following brand names of MS treatments: Aubagio, Avonex, Betaferon or Betaseron, Copaxone, Extavia, Gilenya, Lemtrada, Novantrone, Rebif, Tysabri and Tecfidera using a daily search-time window (i.e. searching for tweets made every day), and specifying the English language. [source, 2014]
Tecfidera had the highest mean score in the all tweet data, and Aubagio had the highest mean score in the filtered for company names and stock/share tweet data. [source, 2014]
Interestingly, the oral MS treatments- Gilenya, Aubagio and Tecfidera had the highest mean sentiment scores and Gilenya had the highest summed sentiment score in all analysis. [source, 2014]
Terifluonamide, laquinimod, and BG-12, do not reduce lymphocyte count in the CNS and appear to act in a similar way to IFN-beta and GA by modulating cytokines and lymphocyte activation. [source, 2014]
None of these injectable (IFN-beta and GA) and oral (terifluonamide, laquinimod, and BG-12) drugs appear to significantly reduce the numbers of circulating lymphocytes, suggesting an immunomodulatory rather than an immunosuppressive profile [7]. [source, 2014]
In a second step, clinical phase III or IV studies on interferon beta-1b, interferon beta-1a, glatiramer acetate, fingolimod, natalizumab, Mitoxantrone and Cyclophosphamide as well as – due to their current importance – studies on laquinimod, teriflunomide, BG-12 and alemtuzumab were extracted. [source, 2014]